HCV genotype 1 infection

The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir )...


Although direct-acting antiviral ( DAA ) therapies for chronic hepatitis C virus ( HCV ) infection have demonstrated high rates...


The European Commission ( EC ) has granted marketing authorization for Vosevi ( Sofosbuvir 400mg / Velpatasvir 100mg / Voxilaprevir...



The FDA ( Food and Drug Administration ) has approved additional indications for Harvoni ( Ledipasvir / Sofosbuvir ) for...


Interim results from one of the ongoing phase II studies of RG-101 for the treatment of hepatitis C virus infection...


A hepatitis C ( HCV ) drug currently under investigation, ABT-493 and ABT-530, which is an all-oral once-daily antiviral treatment,...


Data has demonstrated that choosing a different combination of direct-acting antiviral ( DAA ) treatment for hepatitis C can eradicate...


The European Commission has granted marketing authorization for Epclusa ( Sofosbuvir 400 mg / Velpatasvir 100 mg ), the first...


Researchers have conducted a study to analyze how infection by hepatitis C virus ( HCV ) may influence the immunological...


< br>The European Commission ( EC ) has granted marketing authorizations for Abbvie's all-oral, short-course, Interferon-free treatment of Viekirax (...


Six treatment options are available in 2015 for patients infected with HCV genotype 1, including two IFN-containing regimens and four...


The addition of hepatitis C virus ( HCV ) NS3/4A protease inhibitors to Pegylated-interferon alpha ( PEG-Interferon alpha ) and...


Effective treatment for hepatitis C virus ( HCV ) genotype 1 infection in patients who have not had a sustained...


In this phase 3 trial researchers have evaluated the efficacy and safety of the Interferon-free combination of ABT-450 with Ritonavir...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in...


In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor Sofosbuvir and the NS5A inhibitor Ledipasvir...


The Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ) and the NS5A inhibitor Ombitasvir ( also...


High rates of sustained virologic response were observed among patients with hepatitis C virus ( HCV ) infection who received...


Results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 ( HIV-1 ) co-infection ( TURQUOISE-I...